It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Benzodiazepines exert hypnotic/sedative effects through their inhibitory actions on the γ-aminobutyric acid receptor type A. Since flumazenil antagonises these effects through competitive inhibition of the receptor, it has been used to reverse the effect of benzodiazepines. The goal of this study was to characterise the antagonistic effect of flumazenil on anaesthesia induced by tiletamine-zolazepam in dogs. Nine healthy Beagle dogs (four males, five females) were used in this study. The dogs were administered 20 mg/kg of tiletamine-zolazepam intravenously and were then intravenously treated with saline solution (2 ml; control) or flumazenil twenty minutes after tiletamine-zolazepam administration at doses of 0.02, 0.04, 0.06, 0.08 or 0.16 mg/kg. Recovery times after the anaesthesia and cardiorespiratory variation were recorded for each dog. The results of this study indicate that the duration of reversal produced by doses of 0.04 and 0.06 mg/kg flumazenil was more effective than that produced by any of the other doses. In addition, sedation was rapidly reversible at 0.04 and 0.06 mg/kg without resedation. However, at doses of 0.08 and 0.16 mg/kg adverse effects such as shivering, rigidity and opisthotonos were observed. Thus, treatment with flumazenil at doses of 0.04 and 0.06 mg/kg could successfully reverse the anaesthetic effects induced by tiletamine-zolazepam.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer